Tonix Pharmaceuticals Completes $5.2 Million Underwritten Public Offering
October 31, 2016 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the closing of its previously announced underwritten public offering of...
Tonix Pharmaceuticals to Present Clinical Data at CNS Summit 2016
October 27, 2016 16:32 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD),...
Tonix Pharmaceuticals Prices $5.2 Million Underwritten Public Offering
October 26, 2016 08:46 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the pricing of an underwritten public offering of 9,500,000 units, consisting...
Tonix Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Warrants
October 25, 2016 17:14 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), today announced that it intends to offer shares of its common stock and warrants to...
Tonix Pharmaceuticals to Host Posttraumatic Stress Disorder (PTSD) Awareness Day
October 19, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for PTSD, announced today that it will host...
UPDATE -- Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference
October 18, 2016 17:47 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD),...
Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference
October 13, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD),...
Tonix Pharmaceuticals to Present at 16th Annual Sachs Biotech in Europe Forum
September 26, 2016 09:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD),...
Tonix Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investment Conference
September 07, 2016 07:39 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD),...
Tonix Pharmaceuticals Reports Topline Results from Phase 3 AFFIRM Study of TNX-102 SL in Fibromyalgia and Provides Corporate Update
September 06, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Following Completion of AFFIRM, Tonix to Prioritize Resources for Advancing Posttraumatic Stress Disorder (PTSD) Program into Phase 3 TNX-102 SL Generally Well Tolerated; No New Safety Signals...